Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes

Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer’s disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, revers...

Descripción completa

Detalles Bibliográficos
Autores principales: Pajk, Stane, Knez, Damijan, Košak, Urban, Zorović, Maja, Brazzolotto, Xavier, Coquelle, Nicolas, Nachon, Florian, Colletier, Jacques-Philippe, Živin, Marko, Stojan, Jure, Gobec, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968640/
https://www.ncbi.nlm.nih.gov/pubmed/31914836
http://dx.doi.org/10.1080/14756366.2019.1710502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968640/
https://www.ncbi.nlm.nih.gov/pubmed/31914836
http://dx.doi.org/10.1080/14756366.2019.1710502

Ejemplares similares